Table 1 Sociodemographic, clinical, and smoking-related characteristics of patients who underwent smoking cessation by intensive group counselling or by their GP
IC group (N = 300) | GP group (N = 301) | P value | |||
|---|---|---|---|---|---|
Count (%) | Mean (±SD) | Count (%) | Mean (±SD) | ||
Sociodemographic data | |||||
Age | 47.4 (±11.9) | 44.7 (±12.4) | 0.007 | ||
Gender | |||||
Male | 170 (56.7) | 180 (59.8) | 0.436 | ||
Female | 130 (43.3) | 121 (40.2) | |||
SES Group | |||||
1–3 (low) | 26 (8.7) | 24 (8.0) | |||
4–7 (reference) | 192 (64.0) | 208 (69.1) | 0.399 | ||
8–10 (high) | 82 (27.3) | 69 (22.9) | |||
Presence of Chronic Diseases | |||||
Diabetes Mellitus type 2 | 31 (11.7) | 27 (9.5) | 0.388 | ||
Essential Hypertension | 61 (23.1) | 54 (18.9) | 0.232 | ||
Ischemic Heart Disease | 37 (14) | 28 (9.8) | 0.129 | ||
Chronic Obstructive Pulmonary Disease | 12 (4.5) | 11 (3.9) | 0.689 | ||
History of malignancy | 14 (5.3) | 12 (4.2) | 0.527 | ||
Smoking related variables | |||||
Cigarettes per day | 21.2 (±10.7) | 19.6 (±9.0) | 0.097 | ||
Duration of Smoking, years | 26.1 (±12.0) | 22.6 (±11.7) | < 0.001 | ||
Duration of consumption of Varenicline (months) | 2.3 (±1.45) | 2.2 (±1.45) | 0.180 | ||